Smith and Nephew buys rights to Exogen's ultrasound devices:
This article was originally published in Clinica
Exogen has granted Smith & Nephew US exclusive marketing rights to its ultrasound fracture healing devices, with options for S&N to sell the product internationally. S&N will pay $4.1 million for 7% of Exogen's equity as well as an upfront payment of $1 million. The option to distribute internationally is valued at a further $5 million. In addition S&N can add to its shareholding in the Piscataway, New Jersey-based company.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.